High-grade Vaginal Intraepithelial Neoplasia and Risk of Progression to Vaginal Cancer: a Multicentre Study of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV)
Overview
Pharmacology
Toxicology
Authors
Affiliations
Objective: The aim of this study was to analyse the women with high grade vaginal intraepithelial neoplasia (HG-VaIN), in order to identify a subset of women at higher risk of progression to invasive vaginal cancer.
Materials And Methods: The medical records of all the women diagnosed with HG-VaIN, and subsequently treated, from January 1995 to December 2013 were analyzed in a multicentre retrospective case series. The rate of progression to invasive vaginal cancer and the potential risk factors were evaluated.
Results: 205 women with biopsy diagnosis of HG-VaIN were considered, with a mean follow up of 57 months (range 4-254 months). 12 cases of progression to vaginal squamocellular cancer were observed (5.8%), with a mean time interval from treatment to progression of 54.6 months (range 4-146 months). The rate of progression was significantly higher in women diagnosed with VaIN3 compared with VaIN2 (15.4% vs. 1.4%, p < 0.0001). Women with HG-VaIN and with previous hysterectomy showed a significantly higher rate of progression to invasive vaginal cancer compared to non-hysterectomised women (16.7% vs. 1.4%, p < 0.0001). A higher risk of progression for women with VaIN3 and for women with previous hysterectomy for cervical HPV-related disease was confirmed by multivariable logistic regression analysis.
Conclusions: A higher rate of progression to vaginal cancer was reported in women diagnosed with VaIN3 on biopsy and in women with previous hysterectomy for HPV-related cervical disease. These patients should be considered at higher risk, thus a long lasting and accurate follow up is recommended.
Lu M, Hong X, Liu T, Mai B, Hu G, Sun X BMC Womens Health. 2025; 25(1):44.
PMID: 39893434 PMC: 11786430. DOI: 10.1186/s12905-025-03585-7.
Aune D, Nordsletten M, Myklebust T, Robsahm T, Skalhegg B, Mala T Cancer Causes Control. 2024; 36(2):191-198.
PMID: 39463212 PMC: 11774981. DOI: 10.1007/s10552-024-01930-z.
Chen Y, Guo P, Chen L, He D Front Med (Lausanne). 2024; 11:1370396.
PMID: 39076768 PMC: 11284047. DOI: 10.3389/fmed.2024.1370396.
HiPorfin photodynamic therapy for vaginal high-grade squamous intraepithelial lesion.
Liu Y, Wu R, Li C, Duan L, Wei L, Li R Arch Gynecol Obstet. 2024; 310(2):1197-1205.
PMID: 38900194 PMC: 11258174. DOI: 10.1007/s00404-024-07600-4.
Han Q, Guo H, Wu Z, Shi J, Zhang X Pharmaceutics. 2024; 16(5).
PMID: 38794289 PMC: 11126115. DOI: 10.3390/pharmaceutics16050627.